KZIA - Rasio rega marang prakiraan pendapatan Kazia Therapeutics Ltd

Kazia Therapeutics Limited (KZIA) - logo korporat

Kazia Therapeutics (KZIA) utilizes a flexible drug delivery system to international centers to minimize customs risks and maintain business margins. The forward P/S history demonstrates the issuer's valuation dynamics, where 2126.00 serves as the final level mark. Pipeline development requires strict control of R&D expenditures and the maintenance of liquidity. The specifics of neuro-oncology render the company independent of economic cycles, tying the share price to clinical trial results.

Kazia - Prakiraan rega marang pendapatan KZIA (periode 04.07.2022 - 17.11.2026)

Rincian metrik komprehensif lan analitis Kazia (KZIA)

- rega pasar lan target rega analis:
Analisis umum perusahaan:Kazia Therapeutics Limited KZIA
Produk sing diprodhuksi Kazia Therapeutics Ltd

For Kazia Therapeutics (KZIA), whose valuation depends on the efficacy of paxalisib in treating brain tumors, this indicator determines the market value of the business relative to projected sales. By analyzing the forward P/S ratio, an investor compares current market capitalization with future revenue, which allows for the identification of asset overheating or the discovery of a margin of safety based on the drug's ability to cross the blood-brain barrier.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring Pharma)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep lixte.com (LIXT)|Rasio rega marang prakiraan pendapatan citiuspharma.com|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S BLRX|Multiplikator Forward P/S Can-Fite (CANF)|Rasio rega marang prakiraan pendapatan Aprea Therapeutics Inc. APRE|SLXN (silexion.com) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan